Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years-Reference-Cited by-同舟云学术

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Published:2007-12-03 Issue:1 Volume:24 Page:275-286
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Klonoff David C.¹,Buse John B.²,Nielsen Loretta L.³,Guan Xuesong³,Bowlus Christopher L.⁴,Holcombe John H.⁵,Wintle Matthew E.³,Maggs David G.³

Affiliation:

1. Diabetes Research Institute Mills-Peninsula Health Services, San Mateo, CAUSA

2. Division of Endocrinology, Department of MedicineUniversity of North Carolina School of Medicine Chapel Hill, NCUSA

3. Amylin Pharmaceuticals, Inc. San Diego, CAUSA

4. University of California-Davis Davis, CAUSA

5. Eli Lilly and Co. Indianapolis, INUSA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/030079908X253870

Cited by 580 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Variants in PPARD-GLP1R are related to diabetic kidney disease in Chinese Han patients with type 2 diabetes mellitus;Heliyon;2024-08

2. Simulation-guided development of advanced PID control algorithm for skin cooling in radiofrequency lipolysis;Bio-Medical Materials and Engineering;2024-05-16

3. Long-Term Efficiency of Twice-Daily Exenatide in Type 2 Diabetes Mellitus: A Real-Life Study;ENDOCRINOL RES PRACT;2024

4. Hepatic glucose metabolism in the steatotic liver;Nature Reviews Gastroenterology & Hepatology;2024-02-02

5. The benefits of GLP1 receptors in cardiovascular diseases;Frontiers in Clinical Diabetes and Healthcare;2023-12-08